hotspot -WSS

hotspot

author：Wikipedia 2025-09-30 17:28:25 - browse：85

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Stanford president’s abrupt resignation sparks debate

explore

WSS

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

Startling documents reveal new facets of Sacklers' opioid empire

Average age of first period drops to 11.9 years, study shows

'CMA Fest' 2023: How to watch, who is performing and more

Average age of first period drops to 11.9 years, study shows

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

Wikipedia

hotspot

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

Dark money group runs ads on China biotech bill

Bright Health sells Medicare Advantage business to Molina

Childbirth

At least 13 dead in Texas as scorching temps continue

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

As demand for Covid shots wanes, Moderna seeks its next success

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Moonlake's readout produced a cash windfall. Risks remain

A woman pleads guilty to fire that kept a Wyoming abortion clinic from opening for a year

focus

There’s a way to spot data fakery. All journals should be using it

Average age of first period drops to 11.9 years, study shows

Antibiotic resistance nearly killed me, so I'm raising awareness of it

iTeos Therapeutics debuts first data on TIGIT

Antibiotic resistance nearly killed me, so I'm raising awareness of it

Scientists grapple with ethics of stem cell research

focus

explore

focus

entertainment